Background: Staphylococcus aureus surgical-site infections (SSIs) are a major cause of poor health outcomes, including mortality, across surgical specialties. Despite current advances as a result of preventive interventions, the disease burden of S. aureus SSI remains high, and increasing antibiotic resistance continues to be a concern. Prophylactic S. aureus vaccines may represent an opportunity to prevent SSI.
Introduction
Postoperative surgical-site infections (SSIs) account for 31 per cent of all inpatient healthcare-associated infections and are the most common cause of complications after surgery 1 . SSIs increase length of hospital stay, hospital costs and readmission risk, and worsen health outcomes 2 -7 . SSI is associated with a mortality rate of 3 per cent, and 75 per cent of these deaths are directly attributable to SSI 8 . Treatment is costly and complex, in part owing to increasing drug resistance limiting treatment options 9 -12 . Even with widespread implementation of additional preventive measures, SSIs still substantially burden the healthcare system 13 -16 . In Europe alone, the economic costs of SSI are estimated to range from €1⋅47 to 19⋅1 billion 15 .
Staphylococcus aureus is frequently associated with SSI and prosthetic joint infections, contributing to poor clinical outcomes and increased costs 12,17 -21 . In the USA, methicillin-resistant S. aureus (MRSA) was implicated in 43⋅6 per cent of SSIs in 2011-2014 22 . In England, S. aureus is responsible for 25-40 per cent of orthopaedic and spine surgery SSIs, depending on the procedure type 23 . Given this continued high burden of S. aureus SSI despite current interventions, additional new preventive measures are needed. Vaccines have been proposed as promising preventive interventions against hospital-acquired infections by bacteria such as S. aureus 24, 25 . However, as yet there is no licensed vaccine, despite past attempts to establish the efficacy of two vaccines. This article reviews immunological and pathophysiological research that highlights a potentially successful approach to developing a prophylactic S. aureus vaccine for SSI prevention.
Site of inoculation: the wound
The surgical wound is the primary site of infection initiation, where bacteria enter a normally sterile site that is exposed during the surgical procedure 45 -51 . The two main sources of bacteria are: direct inoculation from a patient colonized with S. aureus 32 or from contaminated healthcare personnel hands or gloves 52 ; and aerosols originating from either the patient (endogenously) or someone else (exogenously, for example a healthcare provider, another patient or a visitor) 53 . Individuals who are persistently colonized by S. aureus have, on average, more than 1 × 10 3 colony-forming units (c.f.u.) of bacteria per nasal swab 54 . A study in humans has shown that wounds containing more than 1 × 10 6 c.f.u. S. aureus per g tissue become infected when closed 55 . This threshold is reduced to 100 c.f.u. with the involvement of foreign bodies, such as sutures 56 , illustrating that a relatively low inoculum of bacteria is sufficient to cause invasive S. aureus SSI. These results further support the assertion that patient contact with S. aureus at the time of surgical incision leads to infection, independent of surgery type.
S. aureus isolates that cause surgical infection are not linked to specific procedure types
S. aureus isolates can be compared by genetic analysis. Every isolate has near-identical house-keeping genes, and comparing the sequences of seven of these permits isolates to be grouped according to relatedness for outbreak control purposes 57, 58 . This approach allows classification into sequence types, which are then grouped into clonal complexes (CCs). There are approximately 15 major S. aureus disease-causing CCs globally 59 . However, none of these is specifically associated with SSI in any given surgical population; rather, S. aureus types from all CCs have been isolated from SSI. Likewise, in situations where hospitals periodically have disease outbreaks caused by specific S. aureus isolates, these infections are not limited to particular surgical procedures. Rather, disease outbreaks are linked to any patient who comes into contact with the outbreak strain either through carriage 38, 60 or from an exogenous source 61 . Thus, both accessibility to a previously sterile site during surgery and the presence of S. aureus during the operation are prerequisites for SSI, but not the type of elective surgery or the S. aureus strain.
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infections using a repertoire of virulence factors. A greater understanding of the virulence mechanisms contributing to the pathogenesis of S. aureus SSI is required for identifying effective candidate vaccine targets. Intriguingly, despite being an invasive pathogen, S. aureus is part of the normal flora of humans, and has evolved to counter most human immune responses 62 . Neutrophil-mediated killing is one of the host's primary immune responses to protect against Gram-positive pathogens. Immediately upon entering the surgical site, S. aureus upregulates expression of its virulence repertoire to adapt to the wound microenvironment and avoid immune-mediated killing 63, 64 . Successful wound infection is facilitated by upregulating the expression of capsular polysaccharides to evade neutrophil-mediated killing 63 -66 , and proteins to adhere to extracellular matrix components and host cells, and to obtain essential nutrients that are limited in the host microenvironment 63,64,67 -81 .
The stages of infection in relation to antigen expression were described by Cheng and colleagues 82 ( Fig. 1) . Stage I corresponds to wound entry followed by pathogen survival in the wound and bloodstream, before dissemination to the organs. As noted above, successful infection of the wound or bloodstream occurs by upregulating bacterial components required to gain access to divalent cations such as manganese transporter protein C (MntC), and to evade immune-mediated killing (for example capsular polysaccharides). S. aureus attaches to damaged host tissues through adhesins such as clumping factor A (ClfA), which binds human fibrinogen. This adhesion is critical for pathogenicity in a mouse model of sepsis, and appears to have an important role in invasive S. aureus disease, including SSI 72 -74 . Once S. aureus transitions from a stage I to a stage II infection, bacterial survival requires the expression of a different repertoire of virulence factors including iron-regulated surface determinant proteins (IsdA, IsdB) and potentially others 82 . If S. aureus infection proceeds through stage II, the formation of mature abscesses or biofilms often occurs. Once established, these disease manifestations are extremely difficult to treat.
Limitations in current infection control and preventive measures
Numerous preventive strategies have reduced SSI in RCTs, and are often delivered as preventive bundles 83 -86 . Those associated with the Surgical Care Improvement Project (SCIP) initiative have been widely adopted in the USA 26 . Additional guidance has been used in Europe, including Epic guidelines 1, 2 and 3 87 , and National Institute for Health and Clinical Excellence (NICE) SSI quality standards 88, 89 . However, no consensus exists on the components of an effective bundle to prevent SSI. Adherence to bundles is labour-intensive for clinical staff, and poor compliance may be one reason for lower than expected effectiveness in SSI reduction in some settings 84 .
Antibiotic prophylaxis is a core intervention for SSI prevention. Antibiotic prophylaxis is recommended to be limited to specific, well accepted, time-limited administration to avoid excess cost, toxicity and antimicrobial resistance, as well as negative impact on the microbiome 90 
Potential of anti-S. aureus vaccines to address increasing antimicrobial resistance
Although antibiotic prophylaxis is currently a cornerstone of SSI prevention, prolonged antibiotic use has been associated with development of resistant organisms 109, 110 and increased SSI risk 111 . In addition, previous antibiotic use is a risk factor for carriage of antibiotic-resistant organisms, such as extended-spectrum β-lactamase-producing Enterobacteriaceae, in surgical patients 112 . It has been estimated that 39-51 per cent of SSIs are caused by pathogens that are resistant to commonly used prophylactic antibiotics 113 . Prolonged and excessive use of antibiotics fosters bacterial resistance and has a negative impact on the microbiome 90 -93 , which may result in complications, such as Clostridium difficile infections 114 . Conceptually, vaccination could elicit a protective immune response, present at the time of incision, with the potential to reduce SSI rates to levels similar to those achieved with antibiotic prophylaxis, while reducing selection pressure for resistant strains.
In addition, an S. aureus-targeted vaccine would not be expected to increase C. difficile infection risk or have other deleterious effects on the gut microbiome. Knowledge about the microbiome of the nasopharynx is limited 115, 116 . Many nasal microbial interactions occur; an anti-S. aureus vaccine may alter colonization dynamics and promote or decrease nasal carriage of other pathogens, as observed with the pneumococcal vaccine in children 117 . In a small pilot study 118 of a now-discontinued S. aureus vaccine candidate (StaphVAX; Nabi Biopharmaceuticals, Rockville, Maryland, USA), S. aureus nasal colonization rates did not significantly change after vaccination 118 . However, the study was underpowered to detect small changes in colonization after vaccination 118 .
Vaccine development considerations
Based on the clinical trial results from investigational S. aureus vaccine candidates, key considerations for developing an effective vaccine to prevent S. aureus SSI appear to be bacterial pathogenesis with respect to vaccine development (vaccine antigen selection), vaccine immunogenicity, and the choice of patient populations for evaluating vaccine efficacy.
Approaches to developing vaccines to prevent surgical-site infection

Anti-S. aureus vaccine has not yet been successful in humans
Vaccines are promising alternatives to antibiotics; however, antistaphylococcal vaccine development has not yet been successful in humans 119 -122 . Seven investigational S. aureus vaccines 123 -134 are currently undergoing development ( Table 1) . In this review, focus is placed on two of the seven investigational S. aureus vaccines that have reached advanced clinical trials (developed by GSK and Pfizer) 123 -127 . Two investigational S. aureus vaccines (developed by Merck and Nabi) that underwent unsuccessful efficacy testing in the past two decades, and are no longer undergoing development, are also reviewed 120, 135, 136 .
The first, StaphVAX (Nabi Biopharmaceuticals), was a vaccine that contained S. aureus capsular polysaccharides type 5 (CP5) and 8 (CP8) conjugated to a non-toxic recombinant Pseudomonas aeruginosa exotoxin A. Capsular polysaccharides by themselves are not preferred vaccine antigens as they do not induce memory responses, and are poorly immunogenic in infants and young children. When conjugated to carrier proteins, however, they can induce antibodies capable of recognizing the capsule, and induce killing of the bacteria in a neutrophiland complement-dependent manner 68, 137 . StaphVAX was administered to patients with end-stage renal disease in two studies 135, 136 to assess efficacy against S. aureus bacteraemia. The vaccine was found to be safe; however, efficacy endpoints were not met in either study. Potential explanations for the lack of efficacy include suboptimal vaccine quality (manufacturing issues) leading to suboptimal induction of protective immune responses, the challenge of protecting an immunocompromised population (such as those with end-stage renal disease) for a prolonged period, and the vaccine's focus on a single bacterial virulence mechanism 136 . The second vaccine, V710, was a non-adjuvanted, single-antigen (IsdB) vaccine developed by Merck (Whitehouse Station, New Jersey, USA). This vaccine was studied in patients undergoing cardiothoracic surgery with median sternotomy 120 . V710 elicited a modest antibody response; however, this response was not shown to facilitate S. aureus killing 119 and, in its efficacy study, the vaccine failed to meet the primary efficacy endpoints 121 . Further, in a post hoc analysis, vaccinated patients who contracted S. aureus invasive disease had an increased risk of death (in some instances associated with multiple organ failure) compared with non-vaccinated patients with S. aureus infections. The reasons for V710's failure to show efficacy and the observed safety signal have not been fully elucidated. However, the most compelling explanation is the fact that V710 did not induce a functional immune response capable of killing the bacteria 120 ; the V710-elicited antibodies were documented only to facilitate uptake of S. aureus by neutrophils (opsonification), but not killing. Other factors that may potentially have contributed to its failure include the use of a single antigen directed against a single virulence mechanism, for which S. aureus has developed multiple redundancies 138 that were not addressed by V710, and the specific clinical characteristics of the efficacy trial population (patients undergoing cardiovascular surgery) 139 .
Designing S. aureus vaccines in consideration of surgical-site infection pathophysiology
V710 and StaphVAX vaccines each addressed only a single virulence mechanism. Although strong evidence exists from other Gram-positive pathogens that capsular polysaccharides are relevant vaccine antigens, S. aureus deploys several additional virulence mechanisms to cause infection. Therefore, a vaccine with the potential to prevent S. aureus SSI should include multiple bacterial components from the organism's arsenal that facilitate infection. Further, a vaccine that induces a functional antibody response to antigens expressed early in the infection process should block or delay the progression of infection while vaccine-elicited memory responses are achieved. Such a vaccine would also be expected to be efficacious across surgical subtypes.
Two investigational vaccines targeting multiple virulence mechanisms involved in S. aureus pathogenicity are currently in advanced clinical development ( Table 1) . The GSK (Rixensart, Belgium) vaccine, combining CP5 and CP8 conjugated to tetanus toxoid, with mutated detoxified α-toxin and ClfA, has completed a phase I clinical trial (registration NCT01160172). No safety concerns were observed, and the vaccine elicited an increase in functional humoral antibody responses that could kill CP5-expressing strains in opsonophagocytic assays 127 , which are used widely to evaluate the efficacy of vaccine candidates by measuring functional immune responses 140 -142 . Another vaccine, in development by Pfizer (Pearl River, New York, USA), the S. aureus four-antigen vaccine (SA4Ag), combines the capsular polysaccharides CP5 and CP8 conjugated to the carrier protein CRM197 (a non-toxic mutant form of diphtheria toxin), a mutated recombinant ClfA (rmClfA, which lacks plasma fibrinogenbinding activity 143 ) and a recombinant form of MntC. SA4Ag was designed to address S. aureus virulence factors that are deployed early during infection. As part of the preclinical development of SA4Ag, the expression of these four antigens was evaluated in wound and bacteraemia models of infection in mice. The results from these studies have demonstrated that all four antigens are expressed in these environments, and expression of at least one of these is detected within 4-6 h after wound infection and 1-4 h after bacteraemic infection 80, 144 . Each of the four antigens in SA4Ag was specifically selected, and demonstrated in both non-clinical and clinical studies to elicit robust functional antibody responses, with no safety concerns 80,145 -147 . In addition, each antigen was demonstrated preclinically to elicit functional antibody responses and/or protect in animal models of infection 71, 80, 146 . For example, anti-ClfA immune responses, which interrupt the ability of S. aureus to adhere to fibrinogen, were able to abrogate ClfA-mediated virulence completely in a murine systemic infection model 146 . Likewise, anti-MntC responses, which deprive S. aureus of the ability to take up manganese and thus detoxify the neutrophil respiratory burst, also ameliorated disease in a systemic infection model 80, 148 . Finally, the attractiveness of capsular polysaccharides as S. aureus vaccine targets has been documented extensively, even in highly stringent animal models such as endocarditis 71, 137, 149, 150 . In two phase I/IIa studies 123, 125 conducted in healthy adults aged 18-64 and 65-85 years, SA4Ag elicited rapid and robust immune responses to each of the four antigens, which were sustained well above baseline for at least 12 months. Opsonophagocytic bacterial killing responses were observed against both CP5-and CP8-expressing S. aureus strains, at levels approximately more than 60-fold and greater than 20-fold above baseline respectively, at day 29 after vaccination. The vaccine was well tolerated, with no safety concerns. These results are promising and support the continued development of SA4Ag. However, there is no established immune correlate of protection; therefore, clinical efficacy studies are required to demonstrate protection against S. aureus disease.
Proposed mechanism of action of vaccines in preventing S. aureus surgical-site infection
In a model of infection, stage I corresponds to wound entry followed by pathogen survival in the wound and bloodstream and before dissemination to the organs (Fig. 1) . When S. aureus transitions from a stage I to a stage II infection, it may then progress to the formation of mature abscesses or biofilms. Given the various stages of infection, the most viable approach to prevent S. aureus infection is to elicit antibacterial immune responses through vaccination before the period of risk (elective surgery), and have the immune responses target the bacterial virulence factors expressed and required in the early infection stages. Antibodies elicited through vaccination will have the same access to implants as human matrix proteins, so would potentially be able to preclude bacterial attachment to the implant, preventing biofilm formation and subsequent dissemination (Fig. 2) . it is important to select an appropriate and clearly defined surgical population for initial evaluation of vaccine efficacy and safety. The study population must be at high risk of invasive S. aureus infection within a predictable time interval, and sufficiently healthy to mount an effective immune response after vaccination 151 . SA4Ag vaccine is being evaluated in elective spinal fusion surgery as a suitable population to demonstrate vaccine safety and efficacy for several reasons. Deep and organ/space SSI rates are relatively high (approximately 2 per cent) 152 , and most commonly occur within 90 days after the procedure 153 , facilitating follow-up and identification of infection events. The co-morbidities of this population are representative of those in healthy populations of the age group studied (mean age 56 years) and other elective surgery populations with usually few immunocompromising conditions 154 . SA4Ag is currently the only anti-S. aureus vaccine under investigation in a clinical efficacy trial. The STRIVE (STaphylococcus aureus suRgical Inpatient Vaccine Efficacy) study is evaluating the ability of SA4Ag to prevent S. aureus SSI in patients undergoing elective open posterior spinal fusion procedures with multilevel instrumentation (NCT02388165) 155 . 
Discussion
Despite implementation of numerous infection control measures, SSI remains a leading cause of postoperative complications, and antibiotic resistance continues to be a concern that limits treatment options. SSIs are the biological summation of several factors: the bacterial inoculum introduced into the wound (primarily during the procedure), the contaminating pathogen's unique virulence, the microenvironment of a surgical wound, and the integrity of the patient's host defence mechanisms. There is a clear unmet need for novel means of preventing postoperative S. aureus SSI. The development of a safe and effective S. aureus vaccine remains one of the best options to prevent disease in the long term, and will have a significant public health impact not only in reducing the S. aureus SSI disease burden but also in reducing the risk of future antimicrobial resistance. A greater understanding of the immunopathogenesis of invasive S. aureus SSI has led to development of multiple-antigen prophylactic vaccine candidates targeting multiple virulence mechanisms.
A vaccine that has the ability to prevent establishment of infection is expected to be efficacious across surgical subtypes owing to commonalities in pathogenesis of infection, patient demographics and co-morbidities. In the coming years, it is highly likely that an effective and safe vaccine able to prevent S. aureus SSI will emerge, resulting in a reduction in the morbidity, mortality and healthcare costs associated with SSI.
